查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018454

心血管醫療設備市場：2026-2032年全球市場預測（按器材類型、手術類型、入路方式、應用和最終用戶分類）

Cardiovascular Devices Market by Device Type, Operation Type, Access Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年心血管醫療設備市場價值為637.7億美元，預計2026年將成長至686.9億美元，複合年成長率為8.06%，到2032年將達到1,097.9億美元。

主要市場統計數據
基準年 2025 637.7億美元
預計年份：2026年 686.9億美元
預測年份 2032 1097.9億美元
複合年成長率 (%) 8.06%

這是一本簡明權威的心血管醫療設備市場指南，涵蓋了醫院、門診診所和居家醫療機構的相關人員的臨床需求、技術轉折點、監管趨勢和戰略重點。

心血管醫療設備業正處於轉折點，其驅動力來自臨床需求、技術進步和不斷變化的監管預期。臨床醫生日益尋求能夠提高診斷準確性、減輕手術負擔並實現長期遠端監測的解決方案，而保險公司則要求產品在治療效果和成本效益方面具有可證明的價值。在此背景下，製造商必須在縮短產品開發週期和提高證據要求之間取得平衡，而醫療保健系統則必須在有限的財力和人力資源下調整併平衡創新。

對改變心血管醫療設備，包括數位化、微創療法的普及、不斷變化的監管以及供應鏈的韌性。

多項變革正在重塑心血管醫療設備的研發、應用和報銷模式。首先，臨床醫師希望縮短住院時間和加快復健速度，加之器材輸送系統和影像引導技術的不斷改進，正在加速向微創和經皮治療的轉變。這一趨勢對臨床路徑產生了連鎖反應，增加了對相容的診斷工具以及術前術後管理設備的需求，同時也重塑了介入團隊的訓練要求。

對 2025 年美國徵收的關稅對醫療器材採購、定價策略、供應商合約、臨床採購和跨境投資決策的累積影響進行重點分析。

美國在2025年實施的關稅政策，為整個心血管醫療設備生態系統的採購、製造和定價策略帶來了新的複雜性。關稅導致零件和組件的投入成本增加，可能會擠壓製造商的利潤空間，促使他們重新評估採購地點和合約條款。在許多情況下，採購團隊正在考慮實施多源採購、雙源採購和策略性庫存緩衝策略，以確保生產的連續性並履行對客戶的承諾。

基於洞察的細分分析，揭示設備類別、操作/存取方法、臨床應用和最終用戶趨勢，從而決定臨床部署模式和採購優先事項。

精細的細分觀點闡明了不同醫療設備類別、手術方式、接取技術、臨床應用和終端用戶環境如何相互作用，從而影響醫療器材的普及趨勢和採購優先順序。在考慮醫療設備類型時，診斷和監測設備（包括心電圖 (ECG) 系統、電極導線和附件、心臟事件記錄器、心電圖監測和植入式循環記錄器）的連接性、數據品質以及與醫療路徑的整合性日益受到重視。外科器械（例如心臟支架、導管、心臟瓣膜和血管移植物）的評估重點在於其傳輸特性、生物相容性材料以及在重複成像和治療流程下的耐久性。對於治療器材（包括血壓計、去心房顫動和心律調節器），則需要提供關於長期可靠性、電池壽命創新以及與遠端追蹤平台相容性的具體證據。

從區域策略觀點審視美洲、歐洲、中東和非洲以及亞太地區如何影響創新管道、監管路徑、償還模式和商業化途徑。

區域趨勢對監管路徑、報銷框架和商業化策略有顯著影響，因此需要採取因地制宜的策略。在美洲，監管機構和大規模綜合醫療保健系統正在推動那些能夠展現出明確臨床和經濟效益的解決方案的快速普及。在採購方面，集中競標在某些醫療保健系統中較為常見，而分散採購則在私人醫院和門診診所更為普遍。差異化的銷售策略和循證策略對於應對這些差異至關重要。

對企業策略進行實際評估，展示研發重點、垂直整合、夥伴關係、監管參與和以結果為導向的商業模式如何塑造競爭地位。

心血管醫療設備領域的主要企業正將深厚的臨床研究與生態系統導向策略結合。投資重點高度集中於將數位化能力與核心設備功能融合，並與軟體和分析公司合作，從設備舉措的數據中提取臨床見解。研發組合日益體現出產品迭代改進與平台計畫之間的平衡，從而實現模組化升級和擴展服務交付。

產業領導者為研發設計、監管策略、商業化和供應鏈韌性與臨床需求和支付方期望保持一致提供了切實可行的策略建議。

產業領導者應優先進行一系列綜合性工作，將策略意圖轉化為實際營運成果。首先，應在產品開發的早期階段納入證據收集工作，設計臨床試驗，同時捕捉臨床終點和真實世界表現指標。這種雙軌證據體係有助於監管申報，並透過展示以病人為中心的療效和系統層面的潛在成本節約，增強與支付方的談判。

調查方法的透明度，包括用於確保分析的嚴謹性和可重複性的初級和次級調查方法的細節、專家檢驗、數據三角測量和品管。

本研究途徑結合了專家的結構化一手訪談和對二手證據的嚴格整合，以確保分析的穩健性。一手數據包括對介入性心臟病專家、電生理學家、採購經理、支付方和前監管審查員的訪談，旨在識別實際限制、未滿足的臨床需求以及影響採購決策的因素。除這些定性研究結果外，我們還透過與臨床試驗負責人和衛生經濟學家的諮詢會議檢驗了證據優先排序和終點選擇。

簡明扼要的結論重點強調了相關人員應優先考慮的策略挑戰、營運風險和短期行動，以維持臨床影響和商業性可行性。

總之，心血管醫療設備市場正經歷一場結構性變革，推動著整合化、主導和數位化解決方案的發展。臨床對微創、可靠且互聯設備的需求與支付方對可驗證價值的期望相融合，提高了市場准入和持續推廣的門檻。價格壓力和供應鏈的複雜性加劇了營運的緊迫性，凸顯了製定穩健的籌資策略和動態定價模式的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：心血管醫療設備市場：依器材類型分類

  • 診斷和監測設備
    • 心電圖系統
    • 電極導線和配件
    • 心臟事件記錄器
    • 心電圖監測
    • 植物型循環記錄器
  • 外科器械
    • 心臟支架
    • 導管
    • 心臟瓣膜
    • 血管移植
  • 治療設備
    • 血壓監測儀
    • 去心房顫動
    • 心律調節器

第9章：心血管醫療設備市場：依手術類型分類

  • 侵入性設備
  • 非侵入式設備

第10章 心血管醫療設備市場：依進入方式分類

  • 經皮
  • 靜脈

第11章：心血管醫療設備市場：依應用領域分類

  • 心律管理
  • 冠狀動脈疾病
  • 周邊血管疾病
  • 中風管理

第12章 心血管醫療設備市場：依最終用戶分類

  • 門診手術中心
  • 居家照護
  • 醫院和診所

第13章 心血管醫療設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 心血管醫療設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 心血管醫療設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：心血管醫療設備市場

第17章 中國：心血管醫療設備市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ACS Diagnostics
  • Alivecor, Inc.
  • Asahi Kasei Corporation
  • B. Braun SE
  • Baxter International Inc.
  • Bexen Medical
  • Biotronik SE & Co KG
  • Boston Scientific Corporation
  • BPL Medical Technologies Private Limited
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • HeartFlow Holding, Inc.
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV,
  • Lepu Medical Technology（Beijing）Co.,Ltd.
  • LivaNova PLC
  • Medtronic PLC
  • Microport Scientific Corporation
  • Nihon Kohden Corporation
  • Schiller AG
  • Siemens Healthineers
  • Terumo Cardiovascular Systems Corporation
  • Tricog Health
  • Vesalius Cardiovascular Inc.
  • Zoll Medical Corporation
Product Code: MRR-D2073C5D8E6E

The Cardiovascular Devices Market was valued at USD 63.77 billion in 2025 and is projected to grow to USD 68.69 billion in 2026, with a CAGR of 8.06%, reaching USD 109.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 63.77 billion
Estimated Year [2026] USD 68.69 billion
Forecast Year [2032] USD 109.79 billion
CAGR (%) 8.06%

A concise and authoritative orientation to the cardiovascular devices landscape framing clinical needs, technology inflection points, regulatory dynamics, and strategic priorities for stakeholders across hospitals, ambulatory care, and home settings

The cardiovascular devices ecosystem stands at an inflection point driven by converging clinical imperatives, technology advances, and evolving regulatory expectations. Clinicians increasingly demand solutions that deliver diagnostic precision, reduce procedural trauma, and enable longitudinal remote monitoring, while payers push for demonstrable value in outcomes and cost effectiveness. Against this backdrop, manufacturers must reconcile shorter product development cycles with higher evidentiary demands, and health systems must balance adoption of innovation against constrained capital and workforce capacity.

Technological convergence is reshaping how devices are designed, validated, and integrated into care pathways. Digital health enablers such as embedded sensors, connectivity platforms, and AI-driven analytics are augmenting traditional device functionality, enabling more proactive disease management and real-world performance assessment. Simultaneously, advances in materials science and minimally invasive techniques are improving safety profiles and expanding eligibility for interventional therapies. These shifts prompt a reorientation of commercial strategies, clinical trial design, and post-market surveillance to capture longitudinal outcomes and support reimbursement narratives.

Transitioning from product-centric to ecosystem-centric approaches will be critical for sustained success. Companies that align their R&D investments with clear clinical endpoints, cultivate payer engagement early, and demonstrate operational readiness for global regulatory and supply chain complexities will be better positioned to translate technological promise into meaningful patient and system-level impact. This report opens with an orientation to these forces to equip leaders with a structured view of the landscape and the strategic choices that follow.

An in-depth examination of transformative shifts altering cardiovascular device development and delivery including digitization, minimally invasive adoption, regulatory evolution, and supply chain resilience

Several transformative shifts are redefining how cardiovascular devices are developed, adopted, and reimbursed. First, the trajectory toward minimally invasive and percutaneous interventions has accelerated, driven by clinician preference for reduced hospital stays and faster recovery, and by iterative improvements in device delivery systems and imaging guidance. This trend has ripple effects across clinical pathways, amplifying demand for compatible diagnostic tools and peri-procedural management devices, while reshaping training requirements for interventional teams.

Second, digitization and connectivity have moved beyond incremental features to become core product differentiators. Devices that provide secure telemetry, integrate with electronic health records, and enable predictive analytics add tangible value by supporting remote monitoring, adherence tracking, and early detection of device-related complications. These capabilities, however, introduce new challenges in cybersecurity, data governance, and interoperability standards that manufacturers and health systems must address collaboratively.

Third, regulatory ecosystems are evolving to accommodate novel device paradigms and software-driven functionality. Regulators are increasingly emphasizing real-world evidence and post-market data collection to complement pre-market evaluations. This shift incentivizes device developers to build robust post-market surveillance and data capture mechanisms into product lifecycles, and to engage with regulatory authorities through early scientific advice and flexible evidence generation strategies.

Fourth, supply chain resilience and sourcing strategies have gained strategic importance. The global distribution of component suppliers, concentration risks for critical materials, and geopolitical dynamics are prompting companies to adopt diversified sourcing, nearshoring where feasible, and contractual structures that mitigate tariff exposure and capacity disruptions. These operational shifts often require investment in supplier qualification, inventory management, and scenario planning.

Lastly, stakeholder expectations around value-based outcomes and cost transparency are influencing procurement and contracting models. Payers and providers are seeking evidence that devices contribute to reduced total cost of care, improved functional outcomes, and fewer readmissions. As a result, commercial teams must couple clinical evidence with economic modeling and real-world outcome data to support differentiated pricing and contracting approaches. Together, these shifts create both opportunity and complexity, requiring integrated strategies across R&D, regulatory, commercial, and operations functions.

A focused analysis of the cumulative impact of United States tariffs introduced in 2025 on device sourcing, pricing strategies, supplier contracts, clinical procurement, and cross-border investment decisions

The introduction of United States tariffs in 2025 has added a distinct layer of complexity to procurement, manufacturing, and pricing strategies across the cardiovascular device ecosystem. Tariff-induced input cost increases for components and subassemblies can compress manufacturer margins, prompting reassessment of sourcing footprints and contract terms. In many cases, procurement teams are exploring multi-sourcing, dual-sourcing, and strategic inventory buffers to insulate production continuity and protect customer commitments.

Manufacturers with vertically integrated capabilities or localized manufacturing nodes may be better positioned to absorb or mitigate tariff impacts, whereas firms reliant on specialized offshore suppliers face steeper adjustments. This dynamic is accelerating conversations about reshoring or nearshoring for critical components, though capital expenditures and qualification timelines remain material constraints for reconfiguration. Consequently, procurement and operations leaders are weighing the trade-offs between short-term cost absorption, price pass-through to customers, and longer-term investments in supply chain agility.

Clinicians and health systems also feel secondary effects as purchasing cycles and tender evaluations adjust to new cost baselines. Hospitals and ambulatory centers must reconcile budgetary pressures with the clinical imperative to adopt advanced devices that improve outcomes. This tension is encouraging greater emphasis on demonstrable value and contractual innovation, including outcome-based agreements and risk-sharing arrangements that align incentives among manufacturers, providers, and payers.

Finally, tariffs have implications for strategic partnerships and capital allocation. Investors and corporate development teams are recalibrating cross-border deals, licensing arrangements, and manufacturing investments to account for policy-driven cost variability. In this environment, transparent supplier mapping, scenario planning, and proactive engagement with payers and procurement stakeholders are essential to preserve market access and maintain competitive differentiation.

Insight-driven segmentation analysis revealing device categories, operation and access modalities, clinical applications, and end-user dynamics that determine clinical adoption patterns and procurement priorities

A nuanced segmentation lens clarifies how different device classes, operational modalities, access techniques, clinical applications, and end-user settings interact to shape adoption dynamics and procurement priorities. When considering device type, diagnostic and monitoring instruments-spanning ECG systems, electrode leads and accessories, event monitors, Holter monitors, and implantable loop recorders-are increasingly evaluated for their connectivity, data quality, and integration with care pathways. Surgical devices such as cardiac stents, catheters, heart valves, and vascular grafts are being assessed for delivery profile, biocompatible materials, and longevity under repeat imaging and therapeutic algorithms. Therapeutic devices that include blood pressure monitors, defibrillators, and pacemakers require focused evidence on long-term reliability, battery life innovations, and compatibility with remote follow-up platforms.

Operation type delineation between invasive devices and non-invasive devices highlights divergent development and adoption considerations. Invasive therapies often necessitate complex clinical training, lengthy regulatory pathways, and substantive peri-procedural support, while non-invasive devices prioritize ease of use, patient adherence, and outpatient integration. Access type distinctions between transcutaneous and transvenous modalities carry implications for infection risk, procedural logistics, and patient selection criteria, which in turn inform both product design and clinical messaging.

Application-specific segmentation-cardiac rhythm management, coronary artery disease, peripheral vascular disease, and stroke management-demonstrates how therapeutic focus affects evidence requirements and care pathway integration. Devices intended for rhythm management must present clear algorithms for sensing and therapeutic thresholds, while coronary interventions increasingly emphasize lesion-specific deliverability and anti-restenotic performance. Peripheral vascular and neurovascular applications bring their own anatomical and hemodynamic complexities that drive device customization and procedural support systems.

End-user segmentation across ambulatory surgical centers, home care, and hospitals and clinics underlines differing purchasing behaviors, capital constraints, and clinical workflows. Ambulatory surgical centers prioritize devices that enable efficient turnover and predictable perioperative courses. Home care solutions demand patient-centric design, remote monitoring capabilities, and clear instructions for non-clinical caregivers. Hospitals and clinics evaluate devices in the context of enterprise-wide protocols, reimbursement models, and cross-specialty interoperability. Taken together, this layered segmentation approach informs targeted clinical evidence strategies, pricing models, and commercialization pathways that better align with the operational realities of each stakeholder group.

A regional strategic lens exploring how Americas, Europe Middle East & Africa, and Asia-Pacific influence innovation pipelines, regulatory pathways, reimbursement models, and commercialization routes

Regional dynamics materially influence regulatory pathways, reimbursement frameworks, and commercialization strategies, requiring geographically tailored approaches. In the Americas, regulatory agencies and large integrated health systems shape rapid uptake for solutions that demonstrate clear clinical and economic benefits. The procurement environment often involves centralized tendering in certain health systems, but also fragmented purchasing across private hospitals and ambulatory centers, which necessitates differentiated sales and evidence strategies.

In Europe, Middle East & Africa, regulatory harmonization efforts and the diversity of payer models create a mosaic of market access pathways. Countries with centralized HTA processes emphasize comparative effectiveness and cost-consequence analyses, while others rely on negotiated pricing and regional procurement agreements. In several jurisdictions, reimbursement decisions increasingly hinge on real-world performance evidence and registries, encouraging device makers to plan longitudinal evidence generation alongside initial clinical studies.

The Asia-Pacific region presents rapid uptake potential tempered by diverse regulatory maturity and pricing pressures. Markets in this region range from highly sophisticated systems that favor premium, innovation-led solutions to price-sensitive environments where cost-efficiency and local manufacturing partnerships are critical. Localization of clinical data, regulatory engagement, and distribution channel strategies are often decisive factors for commercial success.

Across these geographies, strategic considerations converge around regulatory alignment, local evidence generation, and channel partnerships. Developers must balance global product roadmaps with local regulatory and reimbursement realities, investing in targeted clinical studies and payer engagement plans that reflect regional decision drivers. This regional lens informs sequencing strategies for launches, evidence accumulation plans, and partnership models that optimize access while managing commercial risk.

A pragmatic assessment of corporate strategies showing how R&D focus, vertical integration, partnerships, regulatory engagement, and outcome-oriented commercial models shape competitive positioning

Leading companies in the cardiovascular devices arena are demonstrating a blend of deep clinical focus and ecosystem-oriented strategies. Investment priorities skew toward integrating digital capabilities with core device functionality, partnering with software and analytics firms to extract clinical insights from device-generated data. R&D portfolios increasingly reflect a balance between iterative product improvements and platform initiatives that enable modular upgrades and extended service offerings.

Corporate development activity has two dominant themes: vertical integration of critical manufacturing capabilities to improve resilience and strategic partnerships that accelerate access to complementary technologies or distribution networks. Mergers and acquisitions, as well as licensing deals, are being executed to fill capability gaps-particularly in areas such as advanced materials, device-embedded sensors, and cloud-based analytics. Regulatory savvy is a differentiator; organizations that invest in early and ongoing dialogue with authorities, and that build post-market data capture into their offerings, secure smoother pathway transitions and more persuasive value propositions for payers.

Commercial models are evolving toward outcome-oriented relationships with provider networks and payers. Early adopters are piloting risk-sharing agreements and bundled payment approaches that tie reimbursement to patient outcomes and resource utilization. Additionally, companies that streamline service and consumables logistics, provide robust clinical education, and support hospital workflow integration tend to achieve stronger adoption curves. Overall, company success increasingly depends on aligning product development with scalable services, evidence generation, and adaptive commercial models that respond to payer and provider priorities.

Actionable strategic recommendations for industry leaders to align R&D design, regulatory strategy, commercialization, and supply chain resilience with clinical imperatives and payer expectations

Industry leaders should prioritize a set of integrated actions that translate strategic intent into operational outcomes. First, embed evidence generation into product development from the outset by designing clinical studies that capture both clinical endpoints and real-world performance metrics. This dual evidence stream supports regulatory submissions and strengthens payer negotiations by demonstrating patient-centered outcomes and potential system-level savings.

Second, accelerate digital integration by developing clear roadmaps for device connectivity, data interoperability, and analytics-driven services. Prioritize cybersecurity and data governance early to reduce downstream friction with institutional customers and regulators. Coupling device performance with actionable analytics will enhance clinical utility and create new value-based service propositions.

Third, reassess supply chain strategies through the lens of resilience and cost predictability. Diversify supplier bases for critical components, consider nearshoring for strategic parts when feasible, and implement contractual safeguards that address policy volatility. Scenario-based contingency planning will enable faster responses to tariff or disruption events without sacrificing quality or compliance.

Fourth, tailor commercialization strategies to regional and end-user nuances. Align pricing and access models with local reimbursement realities, invest in targeted local evidence generation where required, and deploy hybrid sales models that blend clinical education, field support, and digital engagement to optimize adoption across hospitals, ambulatory centers, and home care settings.

Finally, pursue selective partnerships and targeted M&A to close capability gaps in materials, software, and manufacturing. Use alliances to accelerate time to market and expand clinical applications, while ensuring that integration plans preserve clinical quality and regulatory compliance. Collectively, these recommendations provide a pragmatic pathway to sustain innovation while managing commercial and operational risks.

Methodological transparency detailing primary and secondary research approaches, expert validation, data triangulation, and quality controls used to ensure analytical rigor and reproducibility

The research approach combined structured primary engagement with subject matter experts and a rigorous secondary evidence synthesis to ensure analytic robustness. Primary inputs included interviews with interventional cardiologists, electrophysiologists, procurement leaders, payers, and former regulatory reviewers to surface practical constraints, unmet clinical needs, and procurement decision drivers. These qualitative insights were complemented by advisory sessions with clinical trialists and health economists to validate evidence priorities and endpoint selection.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical registry analyses, and publicly available manufacturers' technical literature to construct a comprehensive evidence base. Data triangulation techniques were applied to reconcile divergent sources and to validate key assertions about device functionality, clinical adoption patterns, and operational requirements. Where applicable, synthesis of procedural trends and device use-cases was corroborated with clinical practice guidelines and consensus statements.

Quality controls included cross-validation of interview findings against documented clinical outcomes and device performance reports, anonymized verification with additional experts, and iterative refinement of assumptions with advisory panel feedback. The methodology emphasized transparency in data sources and analytical assumptions, and the report includes appendices that document interview categories, literature selection criteria, and validation steps to support reproducibility and client confidence in the findings.

A concise concluding synthesis reinforcing strategic imperatives, operational risks, and near-term actions stakeholders should prioritize to sustain clinical impact and commercial viability

In conclusion, the cardiovascular devices landscape is undergoing structural shifts that favor integrated, evidence-driven, and digitally enabled solutions. Clinical demand for minimally invasive, reliable, and connected devices converges with payer expectations for demonstrable value, creating a high bar for market entry and sustained adoption. Tariff-related pressures and supply chain complexities add operational urgency, underscoring the need for resilient sourcing strategies and dynamic pricing models.

Stakeholders that proactively embed longitudinal evidence capture, pursue targeted regional strategies, and align commercial models with clinical workflows will be better positioned to capture the benefits of innovation while mitigating downside risks. Collaborative approaches among manufacturers, providers, and payers-anchored by transparent data sharing and outcome-based agreements-offer a pragmatic route to scale new technologies and deliver measurable patient benefit. The synthesis presented here is intended to inform strategic choices that balance clinical impact, regulatory certainty, and commercial viability across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Devices Market, by Device Type

  • 8.1. Diagnostic & Monitoring Devices
    • 8.1.1. ECG Systems
    • 8.1.2. Electrode Leads & Accessories
    • 8.1.3. Event Monitors
    • 8.1.4. Holter Monitors
    • 8.1.5. Implantable Loop Recorders
  • 8.2. Surgical Devices
    • 8.2.1. Cardiac Stents
    • 8.2.2. Catheters
    • 8.2.3. Heart Valves
    • 8.2.4. Vascular Grafts
  • 8.3. Therapeutic Devices
    • 8.3.1. Blood Pressure Monitors
    • 8.3.2. Defibrillators
    • 8.3.3. Pacemakers

9. Cardiovascular Devices Market, by Operation Type

  • 9.1. Invasive Devices
  • 9.2. Non-Invasive Devices

10. Cardiovascular Devices Market, by Access Type

  • 10.1. Transcutaneous
  • 10.2. Transvenous

11. Cardiovascular Devices Market, by Application

  • 11.1. Cardiac Rhythm Management
  • 11.2. Coronary Artery Disease
  • 11.3. Peripheral Vascular Disease
  • 11.4. Stroke Management

12. Cardiovascular Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Home Care
  • 12.3. Hospitals & Clinics

13. Cardiovascular Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiovascular Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiovascular Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiovascular Devices Market

17. China Cardiovascular Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. ACS Diagnostics
  • 18.7. Alivecor, Inc.
  • 18.8. Asahi Kasei Corporation
  • 18.9. B. Braun SE
  • 18.10. Baxter International Inc.
  • 18.11. Bexen Medical
  • 18.12. Biotronik SE & Co KG
  • 18.13. Boston Scientific Corporation
  • 18.14. BPL Medical Technologies Private Limited
  • 18.15. Edwards Lifesciences Corporation
  • 18.16. GE Healthcare
  • 18.17. HeartFlow Holding, Inc.
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Koninklijke Philips N.V.,
  • 18.20. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 18.21. LivaNova PLC
  • 18.22. Medtronic PLC
  • 18.23. Microport Scientific Corporation
  • 18.24. Nihon Kohden Corporation
  • 18.25. Schiller AG
  • 18.26. Siemens Healthineers
  • 18.27. Terumo Cardiovascular Systems Corporation
  • 18.28. Tricog Health
  • 18.29. Vesalius Cardiovascular Inc.
  • 18.30. Zoll Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIOVASCULAR DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ECG SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ELECTRODE LEADS & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY EVENT MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOLTER MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY IMPLANTABLE LOOP RECORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY BLOOD PRESSURE MONITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY DEFIBRILLATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PACEMAKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY INVASIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY NON-INVASIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY TRANSVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CARDIAC RHYTHM MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY STROKE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CARDIOVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY SURGICAL DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY OPERATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CARDIOVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)